Donate
Call the Lung HelpLine
Ask a Question
The following text field filters the results that follow as you type. Use Tab to access the results.
  1. Home
  2. Research & Reports
  3. About Our Research
  4. Research News
  5. FeNO Predicts the Dupilumab Response in Patients with Moderate-To-Severe Asthma

Baseline FeNO Independently Predicts the Dupilumab Response in Patients with Moderate-To-Severe Asthma

The Journal of Allergy and Clinical Immunology: In Practice | December 16, 2022

This study found that a biomarker called Fractional exhaled nitric oxide (FeNO) could predict how patients with uncontrolled, moderate-to-severe asthma would benefit from the asthma drug, dupilumab. This is important because it identifies which asthma patients would benefit from this drug, which improves the efficiency of these treatments. Coauthor Thomas Casale, MD is an ACRC Investigator.
Freedom From Smoking Clinic - Cleveland, OH
Cleveland, OH | Jun 25, 2024 LUNG FORCE Walk - Cleveland, OH
Cleveland, OH | Sep 29, 2024
See All Events